Strides Pharma Science Limited (NSE: STAR)
1,359.75
+14.90 (1.11%)
Sep 6, 2024, 3:29 PM IST
Strides Pharma Science Revenue
Strides Pharma Science had revenue of 10.88B INR in the quarter ending June 30, 2024, with 16.94% growth. This brings the company's revenue in the last twelve months to 42.09B, up 14.42% year-over-year. In the fiscal year ending March 31, 2024, Strides Pharma Science had annual revenue of 40.51B with 9.83% growth.
Revenue (ttm)
42.09B
Revenue Growth
+14.42%
P/S Ratio
2.95
Revenue / Employee
14.77M
Employees
2,850
Market Cap
125.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 40.51B | 3.63B | 9.83% |
Mar 31, 2023 | 36.88B | 6.18B | 20.13% |
Mar 31, 2022 | 30.70B | -2.46B | -7.41% |
Mar 31, 2021 | 33.16B | 5.64B | 20.49% |
Mar 31, 2020 | 27.52B | 5.74B | 26.33% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries Limited | 9,252.89B |
Tata Consultancy Services Limited | 2,441.25B |
HDFC Bank Limited | 2,663.37B |
Bharti Airtel Limited | 1,510.49B |
ICICI Bank Limited | 1,686.78B |
Infosys Limited | 1,555.41B |
State Bank of India | 3,319.63B |
Hindustan Unilever Limited | 621.07B |
Strides Pharma Science News
- 2 days ago - Strides Pharma Science share jumps 2.62% after getting USFDA approval for Theophylline Extended-Release tablets - Business Upturn
- 2 days ago - Strides Pharma Science gets USFDA nod for Theophylline Extended-Release tablets - Business Upturn
- 22 days ago - Strides Pharma Science shares at 9-year high after US subsidiary closure - Business Upturn